Neurosense Therapeutics Ltd. NRSN 深 滬
已收盤 08-01 16:00:00 美东时间
1.08
-0.720
-40.00%
華盛通- 最 高1.7742
- 今 開1.75
- 成交量 158.52万股
- 最 低 1.00
- 昨 收 1.80
- 總市值 2590.78万
- 52周最高 2.60
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 0.6355
- 委 比 -87.94%
- 總股本 2398.87万
- 歷史最高 8.18
- 量 比 7.17
- 振 幅 43.01%
- 歷史最低 0.40
- 每 手 1
- 風險率 0.40%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target
D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and maintains $14 price target.
07-10 20:25
美股大行评级 | 潜在涨幅455.56%！Medicus Pharma获D. Boral Capital升目标价至27美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1128971739548127232.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• D. Boral Capital：维持Medicus Pharma(MDCX)"买入"评级，目标价从14美元升至27美元</p> <p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从
05-13 08:50
NeuroSense Completes PrimeC Manufacturing Scale-Up for Canadian Launch
Neurosense Therapeutics Ltd. ( ($NRSN) ) just unveiled an announcement. On May ...
05-07 21:29
NeuroSense Therapeutics Scales-Up Production Of PrimeC To Commercial Scale, Following Phase 2B PARADIGM Study
NeuroSense Announces Global CDMO Selection and Manufacturing Scale-Up, Enabling Rapid Pathway to Commercialization for What is Projected to be a $100-150M Canadian Market OpportunityCAMBRIDGE, Mass., May 7, 2025
05-07 20:48
NeuroSense Therapeutics GAAP EPS of -$0.54
NeuroSense Therapeutics press release (NASDAQ:NRSN): FY GAAP EPS of -$0.54. As of December 31, 2024, NeuroSense had cash of approximately $3.4 million. More on NeuroSense Therapeutics Seeking Alpha’s ...
04-08 15:45
NeuroSense Therapeutics FY 2024 GAAP EPS $(0.54) Beats $(0.60) Estimate
NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.60) by 10 percent. This is a 27.03 percent increase over losses of $(0.74) per share
04-08 05:27
NeuroSense Advances PrimeC Commercialization in Canada
The latest announcement is out from Neurosense Therapeutics Ltd. ( ($NRSN) ). N...
03-19 20:27
Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Elevance Health (ELV) and Genmab (GMAB)
Analysts have been eager to weigh in on the Healthcare sector with new ratings ...
02-04 21:40
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
NeuroSense in Compliance with all Nasdaq Listing Requirements CAMBRIDGE, Mass., Jan. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-stage clinical...
01-06 22:00
NeuroSense Advances ALS Treatment with PrimeC, Boosts Financial Position
Neurosense Therapeutics Ltd. ( ($NRSN) ) has issued an update. NeuroSense Thera...
2024-12-19 00:30
